Advaxis (ADXS) Price Target Lowered to $5.00 at Cantor Fitzgerald
Advaxis (NASDAQ:ADXS) had its price objective reduced by research analysts at Cantor Fitzgerald from $19.00 to $5.00 in a research note issued to investors on Tuesday. The firm currently has an “overweight” rating on the biotechnology company’s stock. Cantor Fitzgerald’s target price suggests a potential upside of 153.81% from the company’s current price.
Several other research firms have also recently weighed in on ADXS. ValuEngine raised shares of Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, February 2nd. HC Wainwright set a $23.00 target price on shares of Advaxis and gave the company a “buy” rating in a research report on Wednesday, December 27th.
Advaxis (NASDAQ ADXS) opened at $1.97 on Tuesday. Advaxis has a twelve month low of $1.75 and a twelve month high of $9.55. The firm has a market cap of $81.84, a P/E ratio of -0.83 and a beta of 1.06.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. grew its position in Advaxis by 7.2% during the second quarter. Vanguard Group Inc. now owns 1,782,990 shares of the biotechnology company’s stock valued at $11,572,000 after buying an additional 119,980 shares during the period. State Street Corp grew its position in Advaxis by 7.8% during the second quarter. State Street Corp now owns 670,134 shares of the biotechnology company’s stock valued at $4,352,000 after buying an additional 48,485 shares during the period. Renaissance Technologies LLC bought a new stake in Advaxis during the fourth quarter valued at approximately $1,398,000. Deutsche Bank AG grew its position in Advaxis by 1,200.1% during the fourth quarter. Deutsche Bank AG now owns 467,324 shares of the biotechnology company’s stock valued at $1,326,000 after buying an additional 431,379 shares during the period. Finally, Northern Trust Corp grew its position in Advaxis by 4.4% during the second quarter. Northern Trust Corp now owns 456,817 shares of the biotechnology company’s stock valued at $2,965,000 after buying an additional 19,434 shares during the period. Institutional investors own 29.79% of the company’s stock.
Advaxis Company Profile
Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.
Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.